Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2013
  • Online publication date: May 2013

27 - Ketamine in treatment-resistant depression

from Section 4 - Specific modalities of treatment

Summary

This chapter discusses complementary and alternative medicine (CAM) treatments preferred by patients with mood disorders. Omega-3 fatty acids are lower in depressed suicide attempters and completers compared with depressed nonattempters, a concentration-dependent effect, suggesting increased suicide risk in individuals with extremely low omega-3 levels. St. John's wort (SJW) has been extensively studied as a monotherapy for the treatment of depression. Among the CAM treatments, evidence supports the use of SJW as a monotherapy, and omega-3, S-adenosyl-methionine (SAMe), and several methylators as augmentation strategies in the treatment of depression. Methodological flaws are a consistent critique of CAM, and larger, longer-term studies are needed to assess CAM efficacy. Interventions such as yoga, acupuncture, and improved nutrition are inherently difficult to blind, complicating their assessment. Clinical experience suggests that CAM may be helpful in engaging patients and useful in the treatment of carefully selected patients.

References

aan het Rot, M., Collin, K.A., Murrough, J.W.et al. (2010). Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry, 67, 139–145.
Abel, K.M., Allin, M.P.G., Kuchrska-PieturaK.et al. (2003). Ketamine alters neural processing of facial emotion recognition in healthy men: An fMRI study. NeuroReport, 14, 387–391.
Abrams, R., Morrison, J.E., Villasenor, A.et al. (1993). Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress, 40, 63–66.
Allaoua, H. and Chicheportiche, R. (1989). Anaesthetic properties of phencyclidine (PCP) and analogues may be related to their interaction with Na+ channels. European Journal of Pharmacology, 163, 327–335.
Anand, A., Charney, D.S., Oren, D.A.et al. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Archives of General Psychiatry, 57, 270–276.
Auer, D.P., Putz, B., Kraft, E.et al. (2000). Reduced glutamate in the anterior cingulate cortex in depression: An in vivo proton magnetic resonance spectroscopy study. Biological Psychiatry, 47, 305–313.
Berman, R.M., Cappiello, A., Anand, A.et al. (2000). Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 47, 351–354.
Bevan, R.K., Rose, M.A., and Duggan, K.A. (1997). Evidence for direct interaction of ketamine with alpha 1- and beta 2-adrenoceptors. Clinical and Experimental Pharmacology and Physiology, 24, 923–926.
Blonk, M.I., Koder., B.G., van den Bemt, P.M.L.A.et al. (2010). Use of oral ketamine in chronic pain management: A review. European Journal of Pain, 14, 466–472.
Bovill, J.G., Clarke, R.S., Davis, E.A., and Dundee, J.W. (1971). Some cardiovascular effects of ketamine in man. British Journal of Pharmacology, 41, 411P–412P.
Breier, A., Malhotra, A.K., Pinals, D.A.et al. (1997). Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. American Journal of Psychiatry, 154, 805–811.
Carr, D.B., Goudas, L.C., Denman, W.T.et al. (2004). Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: A randomized, double-blind, placebo-controlled, crossover study. Pain, 108, 17–27.
Chen, X., Shu, S., and Bayliss, D.A. (2009). HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. Journal of Neuroscience, 29, 600–609.
Clements, J.A., Nimmo, W.S., and Grant, I.S. (1982). Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. Journal of Pharmaceutical Science, 71, 539–542.
Cohen, M.G., Chan, S.L., Bhargava, H.N.et al. (1974). Inhibition of mammalian brain acetylcholinesterase by ketamine. Biochemical Pharmacology, 23, 1647–1652.
Covvey, J.R., Crawford, A.N., and Lowe, D.K. (2011). Intravenous ketamine for treatment-resistant major depressive disorder. Annals of Pharmacotherapy, 46, 117–123.
Curran, H.V. and Morgan, C. (2000). Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction, 95, 575–590.
Curran, H.V. and Monaghan, L. (2001). In and out of the K-hole: a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction, 96, 749–760.
Diaz, J.H. (1997). Intranasal ketamine preinduction of paediatric outpatients. Paediatric Anaesthesia, 7, 273–278.
DiazGranados, N., Ibrahim, L.A., Brutsche, N.E.et al. (2010). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry, 71, 1605–1611.
Duman, R.S. and Monteggia, L.M. (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry, 59, 1116–1127.
Erk, S., Mikschl, A., Stier, S.et al. (2010). Acute and sustained effects of cognitive emotion regulation in major depression. Journal of Neuroscience, 30, 15726–15734.
Fava, M. and Davidson, K.G. (1996). Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics of North America, 19, 179–200.
Finck, A.D. and Ngai, S.H. (1982). Opiate receptor mediation of ketamine analgesia. Anesthesiology, 56, 291–297.
Gelissen, H.P., Epema, A.H., Henning, R.H.et al. (1996). Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. Anesthesiology, 84, 397–403.
Glue, P., Gulati, A., Le Nedelec, M.et al. (2011). Dose- and exposure-response to ketamine in depression. Biological Psychiatry, 70, e9–10; author reply e11–12.
Harrison, N.L. and Simmonds, M.A. (1985). Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. British Journal of Pharmacology, 84, 381–391.
Hashimoto, K. (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews, 61, 105–123.
Heinzel, A., Steinke, R., Poeppel, T.D.et al. (2008). S-ketamine and GABA-A-receptor interaction in humans: An exploratory study with I-123-iomazenil SPECT. Human Psychopharmacology, 23, 549–554.
Hetem, L.A., Danion, J.M., Diemunsch, P.et al. (2000). Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berlin), 152, 283–288.
Hirota, K., Hashimoto, Y., and Lambert, D.G. (2002). Interaction of intravenous anesthetics with recombinant human M1-M3 muscarinic receptors expressed in chinese hamster ovary cells. Anesthesia and Analgesia, 95, 1607–1610, table of contents.
Huge, V., Lauchart, M., Magerl, W.et al. (2010). Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. European Journal of Pain, 14, 387–394.
Ibrahim, L., DiazGranados, N., Luckenbaugh, D.A.et al. (2011). Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuropsychopharmacology and Biological Psychiatry, 35, 1155–1159.
Jevtovic-Todorovic, V., Wozniak, D.F., Benshoff, N.D.et al. (2001). A comparative evaluation of the neurotoxic properties of ketamine and nitrous oxide. Brain Research, 895, 264–267.
Kaube, H., Herzon, J., Kaufer, T.et al. (2000). Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology, 55, 139–141.
Kennedy, S.H., Evans, K.R., Kruger, S.et al. (2001). Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. American Journal of Psychiatry, 158, 899–905.
Ketamine Hydrochloride Injection, USP. Package Insert.
Koo, J.W., Russo, S.J., Ferguson, D.et al. (2010). Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proceedings of the National Academy of Sciences USA, 107, 2669–2674.
Krishnan, V. and Nestler, E.J. (2010). Linking molecules to mood: new insight into the biology of depression. American Journal of Psychiatry, 167, 1305–1320.
Li, N., Lee, B., Liu, R.et al. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329, 959–964.
Lin, L.H., Chen, L.L., Zirrolli, J.A.et al. (1992). General anesthetics potentiate gamma-aminobutyric acid actions on gamma-aminobutyric acid A receptors expressed by Xenopus oocytes: Lack of involvement of intracellular calcium. Journal of Pharmacology and Experimental Therapeutics, 263, 569–578.
Larkin, G.L. and Beautrais, A.L. (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology, 14, 1127–1131.
Lodge, D., Anis, N.A., and Burton, N.R. (1982). Effects of optical isomers of ketamine on excitation of cat and rat spinal neurones by amino acids and acetylcholine. Neuroscience Letters, 29, 281–286.
Louon, A. and Reddy, V.G. (1994). Nasal midazolam and ketamine for paediatric sedation during computerised tomography. Acta Anaesthesiologica Scandinavica, 38, 259–261.
Machado-Vieira, R., Manji, H.K., and Zarate, C.A. (2009). The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist, 15, 525–539.
Maeng, S., Zarate, C.A. Jr., DuJ.et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: Role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry, 63, 349–352.
Malhotra, A.K., Pinals, D.A., Weingartner, H.et al. (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14, 301–307.
Malinovsky, J.M., Servin, F., Cozian, A.et al. (1996). Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. British Journal of Anaesthesia, 77, 203–207.
Mathew, S.J. (2008). Treatment-resistant depression: recent developments and future directions. Depression and Anxiety, 25, 989–992.
Mathew, S.J., Manji, H.K., and Charney, D.S. (2008). Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology, 33, 2080–2092.
Mathew, S.J., Murrough, J.W., aan het Rot, M.et al. (2010). Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: A pilot randomized, placebo-controlled continuation trial. International Journal of Neuropsychopharmacology, 13, 71–82.
Morgan, C.J. and Curran, H.V. (2006). Acute and chronic effects of ketamine upon human memory: A review. Psychopharmacology, 188, 408–424.
Morgan, C.J., Muetzelfeldt, L., and Curran, H.V. (2010). Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction, 105, 121–133.
Morgan, C.J., Mofeez, A., Brander, B.et al. (2004a). Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: A dose-response study. Psychopharmacology, 172, 298–308.
Morgan, C.J., Monaghan, L., and Curran, H.V. (2004b). Beyond the K-hole: A 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction, 99, 1450–1461.
Morris, C., Perris, A., Klein, J.et al. (2009). Anaesthesia in haemodynamically compromised emergency patients: Does ketamine represent the best choice of induction agent?Anaesthesia, 64, 532–539.
Murrough, J.W. and Charney, D.S. (2010). Cracking the moody brain: Lifting the mood with ketamine. Nature Medicine, 16, 1384–1385.
Murrough, J.W., Perez, A.M., Mathew, S.J.et al. (2011). A case of sustained remission following an acute course of ketamine in treatment-resistant depression. Journal of Clinical Psychiatry, 72, 414–415.
Nock, M.K. and Banaji, M.R. (2007). Assessment of self-injurious thoughts using a behavioral test. American Journal of Psychiatry, 164, 820–823.
Olney, J.W., Labruyere, J., Wang., G.et al. (1991). NMDA antagonist neurotoxicity: Mechanism and prevention. Science, 254, 1515–1518.
Paul, I.A., Nowak, G., Layer, R.T.et al. (1994). Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. Journal of Pharmacology and Experimental Therapeutics, 269, 95–102.
Paul, R., Schaaff, N., Padberg, F.et al. (2009). Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: Report of two cases. World Journal of Biological Psychiatry, 10, 241–244.
Pittaluga, A., Raiteri, L., Longordo, F.et al. (2007). Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology, 53, 27–36.
Preskorn, S.H., Baker, B., Kolluri, S.et al. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology, 28, 631–637.
Price, R.B., Nock., M.K., Charney, D.S.et al. (2009a). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry, 66, 522–526.
Price, R.B., Shungu, D.C., Mao, X.et al. (2009b). Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: Relationship to treatment resistance in major depressive disorder. Biological Psychiatry, 65, 792–800.
Reich, D.L. and Silvay, G. (1989). Ketamine: An update on the first twenty-five years of clinical experience. Candian Journal of Anaesthiology, 36, 186–197.
Roelofse, J.A., Shipton, E.A., De La Harpe, C.J.et al. (2004). Intranasal sufentanil/midazolam versus ketamine/midazolam for analgesia/sedation in the pediatric population prior to undergoing multiple dental extractions under general anesthesia: A prospective, double-blind, randomized comparison. Anesthesia Progress, 51, 114–121.
Rosenberg, D.R., Macmaster, F.P., Mirza, Y.et al. (2005). Reduced anterior cingulate glutamate in pediatric major depression: A magnetic resonance spectroscopy study. Biological Psychiatry, 58, 700–704.
Rowland, L.M., Astur, R.S., Jung, R.E.et al. (2005). Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology, 30, 633–639.
Rush, A.J., Trivedi, M.H., Wisniewski, S.R.et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163, 1905–1917.
Rush, A.J., Warden, D., Wisniewski, S.R.et al. (2009). STAR*D: Revising conventional wisdom. CNS Drugs, 23, 627–647.
Salmi, E., Langsjo, J.W., Aalto, S.et al. (2005). Subanesthetic ketamine does not affect 11C-flumazenil binding in humans. Anesthesia and Analgesia, 101, 722–725, table of contents.
Salvadore, G., Corwell, B.R., Colon-Rosario, V.et al. (2009). Increased anterior cingulate cortical activity in response to fearful faces: A neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biological Psychiatry, 65, 289–295.
Salvadore, G., Cornwell, B.R., Sambataro, F.et al. (2010). Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology, 35, 1415–1422.
Sanacora, G., Kendell, S.F., Levin, Y.et al. (2007). Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biological Psychiatry, 61, 822–825.
Sanacora, G., Zarate, C.A., Krystal, J.H.et al. (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery, 7, 426–437.
Seeman, P., Ko, F., and Tallerico, T. (2005). Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Molecuar Psychiatry, 10, 877–883.
Seeman, P., Guan, F.C., and Hirbec, H. (2009). Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. Synapse, 63, 698–704.
Smith, D.J., Pekoe, G.M., Martin, L.L.et al. (1980). The interaction of ketamine with the opiate receptor. Life Sciences, 26, 789–795.
Smith, D.J., Azzaro, A.J., Zaldivar, S.B.et al. (1981). Properties of the optical isomers and metabolites of ketamine on the high affinity transport and catabolism of monoamines. Neuropharmacology, 20, 391–396.
Smith, D.J., Bouchal, R.L., deSanctis, C.A.et al. (1987). Properties of the interaction between ketamine and opiate binding sites in vivo and in vitro. Neuropharmacology, 26, 1253–1260.
Thangathurai, D. and Mogos, M. (2011). Ketamine alleviates fear, depression, and suicidal ideation in terminally ill patients. Journal of Palliative Medicine, 14, 389.
Trivedi, M.H., Thase, M.E., Osuntokun, O.et al. (2009). An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. Journal of Clinical Psychiatry, 70, 387–396.
Tweed, W.A., Minuck, M., and Mymin, D. (1972). Circulatory responses to ketamine anesthesia. Anesthesiology, 37, 613–619.
Valentine, G.W., Mason, G.F., Gomez, R.et al. (2011). The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Research, 191, 122–127.
Vialou, V., Robison, A.J., Laplant, Q.C.et al. (2010). DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nature Neuroscience, 13, 745–752.
Vollenweider, F.X. and Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11, 642–651.
Vollenweider, F.X., Leenders, K.L., Oye, I.et al. (1997a). Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). European Neuropsychopharmacology, 7, 25–38.
Vollenweider, F.X., Leenders, K.L., Scharfetter, C.et al. (1997b). Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). European Neuropsychopharmacology, 7, 9–24.
Weber, F., Wulf, H., and El Saeidi, G. (2003). Premedication with nasal s-ketamine and midazolam provides good conditions for induction of anesthesia in preschool children. Canadian Journal of Anaesthesia, 50, 470–5.
Weber, M., Motin, L., Gaul, S.et al. (2005). Intravenous anaesthetics inhibit nicotinic acetylcholine receptor-mediated currents and Ca2+ transients in rat intracardiac ganglion neurons. British Journal of Pharmacology, 144, 98–107.
Weksler, N., Ovadia, L., Muati, G.et al. (1993). Nasal ketamine for paediatric premedication. Canadian Journal of Anaesthesia, 40, 119–121.
White, P.F., Way, W.L., and Trevor, A.J. (1982). Ketamine – its pharmacology and therapeutic uses. Anesthesiology, 56, 119–136.
Yanagihara, Y., Ohtani, M., Kariya, S.et al. (2003). Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers. Biopharmaceutics and Drug Disposition, 24, 37–43.
Zarate, C.A., Jr., Payne, J.L., Quiroz, J.et al. (2004). An open-label trial of riluzole in patients with treatment- resistant major depression. American Journal of Psychiatry, 161, 171–174.
Zarate, C.A., Jr., Quiroz, J., Singh, J.B.et al. (2005). An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biological Psychiatry, 57, 430–432.
Zarate, C.A., Jr., Singh, J.B., Carlson, P.J.et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 63, 856–864.